Veramed is proud to announce the arrival of Pamela Rennie as Head of Alliance Management. With more than 30 years in the Pharma and CRO industry, Pamela has extensive experience in the field of biometrics, having a previous statistical career covering all phases of drug development, regulatory submissions and commercialisation. Following a secondment in India supporting the outsourcing of clinical trial analysis and reporting to an offshore provider, Pamela moved into an Alliance Management role to support the relationship management of strategic providers working with a large Pharma company. With a proven track record of building productive and collaborative relationships with external clients and cross-functional internal leadership teams in a CRO environment, Pamela understands the importance of providing outstanding quality deliverables and exceptional service to our customers. Prior to joining Veramed, Pam held roles as SVP for Global Customer Relations and Head of Alliance Management at a biometrics CRO, and Director of Alliance Management within a large pharma organization. She obtained her BCs in Mathematics from Coventry University, and an MSc in Statistics from Sheffield University.
About Veramed
Veramed is a high-performing partner that provides a comprehensive suite of data management and biostatistical consulting services to a global client base. The team is dedicated to advancing patient health by integrating people, innovation, and technology. Veramed has been a certified B Corp since 2020, demonstrating its commitment to its people, customers, and the environment.
Named a 2025 Best Companies 3* employer for its outstanding workplace and employee satisfaction, Veramed was also Flexa-verified in 2025 for its commitment to flexible work and prioritizing its people.
Veramed is passionate about making a difference in patient communities around the world. Being uniquely practitioner-led, the company challenges how advanced biometrics services can be used to help move the needle on the speed, quality, and effectiveness of pharma and biotech pipeline delivery.
